Savara Inc. , a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the closing of its previously announced underwritten public offering of 28,452,381 shares ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback